Dr. Chawla is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Lebanon, NH 03756Phone+1 603-650-5000Fax+1 401-444-6378
Education & Training
- University of California (San Francisco)Fellowship, Pediatric Hematology/Oncology, 1998 - 2001
- Tulane UniversityResidency, Pediatrics, 1995 - 1998
- University of Vermont College of MedicineClass of 1995
Certifications & Licensure
- CA State Medical License 1999 - Present
- RI State Medical License 2001 - 2026
- NH State Medical License 2023 - 2025
- MA State Medical License 2004 - 2019
- LA State Medical License 1996 - 1998
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- Cost-Effectiveness of Lovotibeglogene Autotemcel (Lovo-Cel) Gene Therapy for Patients with Sickle Cell Disease and Recurrent Vaso-Occlusive Events in the United States.William L Herring, Meghan E Gallagher, Nirmish Shah, K C Morse, Deirdre Mladsi
Pharmacoeconomics. 2024-06-01 - 5 citationsHeterogeneity of the long-term economic burden of severe sickle cell disease: a 5-year longitudinal analysis.Meghan E Gallagher, Anjulika Chawla, Brenna L Brady, Sherif M Badawy
Journal of Medical Economics. 2022-10-12 - Direct CNS administration of rituximab and epratuzumab in a pediatric patient with relapsed refractory CNS B-cell acute lymphoblastic leukemia.Jenna McClane, Anjulika Chawla, Jennifer J G Welch
Pediatric Blood & Cancer. 2022-06-01
Press Mentions
- Are We About to Cure Sickle-Cell Disease?March 22nd, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: